Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- LIPI.ST
- Price
- 0.26
- Stock movement up
- +0.01 (4.59%)
- Company name
- Lipidor Ab
- Exchange
- (ST ,
- Currency
- SEK )
- Sector
- Healthcare >Drug Manufacturers - General
- Market cap
- 213.11M
- Ent value
- 198.33M
- Price/Sales
- 2567.61
- Price/Book
- 13.08
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- 4.13%
- 1 year return
- 10.08%
- 3 year return
- -69.10%
- 5 year return
- -52.56%
- 10 year return
- -
Last updated: 2025-04-15
DIVIDENDS
LIPI.ST does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 2567.61 |
| Price to Book | 13.08 |
| EV to Sales | 2389.58 |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 813.40M |
| EPS (TTM) | -0.19 |
| FCF per share (TTM) | -0.15 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 83.00K |
| Gross profit (TTM) | -10.01M |
| Operating income (TTM) | -15.21M |
| Net income (TTM) | -13.53M |
| EPS (TTM) | -0.19 |
| EPS (1y forward) | - |
Margins
Loading...
Margins data
| Gross margin (TTM) | -12062.65% |
| Operating margin (TTM) | -18331.33% |
| Profit margin (TTM) | -16300.00% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 22.75M |
| Net receivables | 474.00K |
| Total current assets | 23.84M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 430.00K |
| Total assets | 24.27M |
| Accounts payable | 3.20M |
| Short/Current long term debt | 0.00 |
| Total current liabilities | 7.98M |
| Total liabilities | 7.98M |
| Shareholder's equity | 16.29M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -10.81M |
| Capital expenditures (TTM) | 0.00 |
| Free cash flow (TTM) | -10.81M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -83.04% |
| Return on Assets | -55.75% |
| Return on Invested Capital | -83.04% |
| Cash Return on Invested Capital | -66.35% |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 0.25 |
| Daily high | 0.26 |
| Daily low | 0.25 |
| Daily Volume | 3.71M |
| All-time high | 22.60 |
| 1y analyst estimate | 1.00 |
| Beta | 0.62 |
| EPS (TTM) | -0.19 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | - |
Downside potential
Loading...
Downside potential data
| LIPI.ST | S&P500 | |
| Current price drop from All-time high | -98.84% | -12.04% |
| Highest price drop | -99.81% | -56.47% |
| Date of highest drop | 4 Jul 2024 | 9 Mar 2009 |
| Avg drop from high | -68.79% | -11.07% |
| Avg time to new high | 78 days | 12 days |
| Max time to new high | 1319 days | 1805 days |
COMPANY DETAILS
Marketcap
213.11M
Marketcap category
Small-cap
Description
Lipidor AB (publ), a pharmaceutical development company, engages in the development of drugs for the treatment of psoriasis, acne vulgaris, bacterial skin infections, and atopic dermatitis. The company develops AKP-01, which is in Phase III for the treatment of psoriasis; and preclinical stage products, such as AKP-02 for psoriasis, AKP-03 for bacterial skin diseases, and AKP-07 for atopic dermatitis. It offers active pharmaceutical ingredients used in products for various therapeutic applications, such as anti-psoriasic, antimicrobial, anti-inflammatory, antifungal, local anesthetics, non-steroidal anti-inflammatory, anti-acne, wound healing, anti-eczema, and anti-migraine. The company also develops a range of spray products for animal skin care in dogs, cats, and horses; and consumer health care products for applications, including antibacterial, antiseptic, moisturizing emollient, disinfectant, and acne and wart treatment. It has a collaboration agreement with Cannassure Therapeutics Ltd. for the development of topical medicinal cannabis products for the treatment of skin inflammations and psoriatic lesions. The company was incorporated in 2009 and is based in Danderyd, Sweden.
Employees
5
Website
Investor relations
-
SEC filings
CEO
Country
Sweden
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
No items found